VANCOUVER, British Columbia, Jan. 24, 2019 (GLOBE NEWSWIRE) -- Auxly Cannabis Group Inc. (TSX.V: XLY)
(OTCQX: CBWTF) (the "Company") is pleased to announce that the Company has signed a definitive agreement
(the “Transaction”) with 2368523 Ontario Limited (d/b/a) Curative Cannabis ("Curative"). The
Company will acquire 46% of the common shares of Curative and enter into a long-term cannabis purchase and sale agreement to fund
the construction and development costs of Curative’s cannabis cultivation facility in Chatham-Kent, Ontario (the
“Facility”).
The Facility is designed as a purpose-built indoor facility for the production of ultra-premium cannabis
product. With an initial footprint spanning approximately 30,000 square feet, the first phase of the Facility is expected to yield
approximately 2,900 kg of cannabis per annum. Curative anticipates bringing a unique ultra-premium cannabis product to Canadian
recreational cannabis consumers through its proprietary genetics database of over 90 stable, and highly sought-after, cannabis
strains (the "Genetic Library").
The first phase of the Facility, being built to EU GMP standards, is currently under construction with an anticipated completion
and Health Canada evidence package submission date of March 2019. Curative’s Facility rests on a 33-acre land parcel thereby
providing ample room for Facility expansion. Curative has already received municipal approval for the expansion of the Facility for
up to an additional 120,000 square feet of indoor cultivation space.
Pursuant to the Transaction, the Company has entered into a share purchase agreement with certain shareholders of Curative, whereby
the Company has agreed to purchase 46% of the common shares of Curative from certain Curative shareholders, in exchange for the
issuance of 5,056,026 common shares of the Company (the “Consideration Shares”). The Company will also enter into
a long-term cannabis purchase and sale agreement with Curative, pursuant to which the Company will fund the construction and
development costs of the Facility in exchange for the right to purchase 50% of the cannabis products and cannabis trim produced at
the Facility at an offtake price equal to Curative’s direct cost of cultivation plus 10%.
Additionally, the Company shall be granted: (i) a right of first refusal over any future expansion of the Facility and/or the
proposed construction of any new cannabis production facility by Curative and if the Company exercises such right of refusal it
shall be entitled to receive a comparable offtake purchase arrangement as it received under the Transaction; and (ii) unfettered
access and control to Curative’s Genetic Library which can be transferred (at the Company's discretion), used and cultivated by the
Company’s properly licensed subsidiaries, affiliates or commercial partners.
Hugo Alves, President and Director of Auxly Cannabis Group commented: “Curative is a highly valued partner to Auxly, having been a
part of the Auxly family since the inception of the Company. That being said, we could not be more pleased to have reached this
stage of the project and to be signing a definitive agreement with Curative. Curative’s optimization of indoor cultivation combined
with their unique genetics will provide a highly desirable product offering to the Canadian recreational cannabis markets and to
the Auxly platform as a whole. We are pleased to be working with Dave, Scott and their team as they build out additional phases of
this project and bring their product to market.
On a related note, we would like to thank the municipality of Chatham-Kent for the tremendous support they have provided to the
Curative project. We look forward to continuing to work with the municipality of Chatham-Kent to create economic value in the
region.”
Closing of the Transaction is subject to customary closing conditions, including: (i) the execution of the long-term cannabis
purchase and sale and a unanimous shareholders’ agreement with the Curative shareholders, and (ii) the acceptance of the TSX
Venture Exchange. The Consideration Shares will be subject to a statutory hold period of four months and one day, in accordance
with applicable securities laws.
ON BEHALF OF THE AUXLY BOARD
"Chuck Rifici" Chairman & CEO
About Auxly Cannabis Group Inc. (TSX.V: XLY) (OTCQX: CBWTF)
Auxly is a vertically integrated cannabis company with diverse operations across Canada and Uruguay. The company
was formed with the primary intent of providing financing solutions to cannabis licence applicants, and has evolved into a platform
spanning the entire cannabis value chain. Auxly’s management believes that a vertically integrated model, adapted for the cannabis
space, allows for substantive control over its operations through increased operational flexibility, economic resiliency and
improved product margin dynamics in an effort to create long term shareholder value. Auxly currently operates three distinct, yet
synergistic, segments:
• Upstream – Auxly’s diverse cannabis cultivation platform across its streaming partners, joint ventures and
wholly-owned subsidiaries;
• Midstream – Auxly’s processing and development platform focused on the development of proprietary
cannabis-derived products and related intellectual property to address consumer needs through its wholly-owned subsidiary,
Dosecann; and
• Downstream – Auxly’s medical, recreational and international distribution platform.
Investor Relations:
For more information about investing in Auxly Cannabis Group Inc., please visit: http://www.auxly.com or contact our Investor
Relations Team:
Email: IR@auxly.com
Phone: 1.833.695.2414
Stay Connected:
Follow up on Twitter @AuxlyGroup
Media Enquiries (only):
For media enquiries or to set up an interview please contact:
Sarah Bain, VP External Affairs
Email: sarah@auxly.com
Phone: 613.230.5869
Notice Regarding Forward Looking Information:
This news release contains certain "forward-looking information" within the meaning of applicable Canadian
securities law. Forward-looking information is frequently characterized by words such as "plan", "continue", "expect", "project",
"intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or information that
certain events or conditions "may" or "will" occur. This information is only a prediction. Various assumptions were used in drawing
the conclusions or making the projections contained in the forward-looking information throughout this news release.
Forward-looking information includes, but is not limited to: the ability of the Company to obtain the necessary regulatory
approvals to complete the Transaction, including receipt of the approval of the TSX Venture Exchange, expectations of future
growing capacity at the Facility and the related costs, the completion of the planned build-out and expansions, including the
timing thereof, requirements to obtain additional financing for such build-out and expansions, the ability to satisfy the
conditions required to obtain the Facility’s cultivation and sales license, timeliness of government approvals for granting of
permits and licenses, actual operating performance of the Facility, the growth of Curative and timing thereof, regulatory or
political change, competition and other risks affecting the Company in particular and the cannabis industry generally.
A number of factors could cause actual results to differ materially from a conclusion, forecast or projection
contained in the forward-looking information in this release including, but not limited to, whether: either the Company or Curative
being unable comply with its respective obligations under the agreements governing the Transaction, failure of Curative to complete
construction of Facility on the timeline indicated or at all, failure of Curative to obtain the required licenses to cultivate and
sell cannabis products, and general economic, financial market, regulatory and political conditions in which the Company operates
will remain the same. Additional risk factors are disclosed in the revised annual information form of the Company for the financial
year ended December 31, 2017 dated May 24, 2018.
New factors emerge from time to time, and it is not possible for management to predict all of those factors or
to assess in advance the impact of each such factor on the Company's business or the extent to which any factor, or combination of
factors, may cause actual results to differ materially from those contained in any forward-looking information. The forward-looking
information in this release is based on information currently available and what management believes are reasonable assumptions.
Forward-looking information speaks only to such assumptions as of the date of this release. In addition, this release may contain
forward-looking information attributed to third party industry sources, the accuracy of which has not been verified by the Company.
The purpose of forward-looking information is to provide the reader with a description of management's expectations, and such
forward-looking information may not be appropriate for any other purpose. Readers should not place undue reliance on
forward-looking information contained in this release.
The forward-looking information contained in this release is expressly qualified by the foregoing cautionary
statements and is made as of the date of this release. Except as may be required by applicable securities laws, the Company does
not undertake any obligation to publicly update or revise any forward-looking information to reflect events or circumstances after
the date of this release or to reflect the occurrence of unanticipated events, whether as a result of new information, future
events or results, or otherwise.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
